A. Long-term therapy consisting of 3 months of treatment with a vitamin K antagonist (VKA) over any other anticoagulation therapy B. Long-term therapy consisting of 3 months of treatment with dabigatran, rivaroxaban, apixaban, or edoxaban over VKA therapy C. Longer-term therapy consisting of 1 year of treatment with a VKA over any other anticoagulation therapy D. Longer-term therapy consisting of 1 year of treatment with dabigatran, rivaroxaban, apixaban, or edoxaban over VKA therapy

A. “In general, DOACs provide superior efficacy and possibly a better safety profile compared with warfarin.” B. “In general, DOACs provide superior efficacy and a greatly improved safety profile compared with warfarin.” C. “In general, DOACs provide comparable efficacy and possibly a better safety profile than warfarin.” D. “In general, DOACs provide comparable efficacy and a greatly improved safety profile than warfarin.”

A. A patient's overall risk for developing thrombosis B. A patient's risk of experiencing drug interactions based on patient-specific factors (ie, comorbidities) C. A patient's risk of developing adverse events based previous medication experience(s) D. Dosing regimens to minimize the patient's risk of adverse events

A. “Less than 50% of all episodes of VTE occur in the outpatient setting.” B. “About 50% of all episodes of VTE occur in the outpatient setting.” C. “The vast majority of all episodes of VTE occur in the outpatient setting.” D. “No conclusive evidence suggests there is any difference in the risk of VTE for inpatients versus outpatients.”

A. DOACs (eg, apixaban, betrixaban, dabigatran, edoxaban, rivaroxaban) B. Low-molecular-weight heparin (eg, enoxaparin) C. Unfractionated heparin D. VKAs (eg, warfarin)